GABAPENTIN FOR RELIEF OF UPPER MOTOR-NEURON SYMPTOMS IN MULTIPLE-SCLEROSIS

Objective: To examine the efficacy of gabapentin in the treatment of s pasticity and painful muscle spasms in patients with multiple sclerosi s. Design: Double-blind, placebo-controlled crossover study. Setting: Free-standing, 93-bed, university-affiliated rehabilitation hospital.P articipants: There were 15 patients between the ages of 18 and 50 who had laboratory-supported definite multiple sclerosis with spasticity a nd leg cramps severe enough to interfere with daily activities, includ ing sleep. Intervention: The patients received the placebo or 400mg ga bapentin orally three times a day for 48 hours with an 11-day washout period. If the patients were on currently accepted modes of therapy, i ncluding oral baclofen, their current medication was not changed. Main Outcome Measures: The outcome measures were Visual Faces Scale rating , Kurtzke Disability Scale, quantitative surface electromyography, Ash worth Scale, presence or absence of clonus in response to rapid ankle dorsiflexion and wrist extension, presence or absence of reflex withdr awal in response to nailbed pressure to the first finger, and assessme nt of Babinski response. Results: Statistically significant improvemen ts for the gabapentin-treated patients were found in the Ashworth Scal e, Visual Faces Scale, and Kurtzke Disability Scale. Conclusions: At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienc ed by patients with multiple sclerosis. (C) 1997 by the American Congr ess of Rehabilitation Medicine and the American Academy of Physical Me dicine and Rehabilitation.